TY - JOUR
T1 - Reliability and validity of the Thai Drug Hypersensitivity Quality of Life Questionnaire
T2 - A multi-center study
AU - Chongpison, Yuda
AU - Rerknimitr, Pawinee
AU - Hurst, Cameron
AU - Mongkolpathumrat, Pungjai
AU - Palapinyo, Sirinoot
AU - Chularojanamontri, Leena
AU - Srinoulprasert, Yuttana
AU - Rerkpattanapipat, Ticha
AU - Chanprapaph, Kumutnart
AU - Disphanurat, Wareeporn
AU - Chakkavittumrong, Panlop
AU - Tovanabutra, Napatra
AU - Srisuttiyakorn, Chutika
AU - Sukasem, Chonlaphat
AU - Tuchinda, Papapit
AU - Baiardini, Ilaria
AU - Klaewsongkram, Jettanong
N1 - Funding Information:
Authors thank the WHO for the permission to use WHOQOL-BREF-Thai Questionnaire. This study has been supported by (i) Rachadapisek Sompote Fund for Postdoctoral Fellowship, Chulalongkorn University; (ii) the Skin and Allergy Research Unit, Chulalongkorn University and the National Research University Project, Office of Higher Education Commission (WCU-002-HR-57); and (iii) the Thailand Research Fund (RSA5880041). Study data were collected and managed using Research Electronic Data Capture (REDCap) hosted at HIV Netherlands Australia Thailand Research Collaboration.
Publisher Copyright:
© 2018 The Author(s) 2018. Published by Oxford University Press in association with the International Society for Quality in Health Care. All rights reserved.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Objective: To adapted the Drug Hypersensitivity Quality of Life (DrHy-Q) Questionnaire from Italian into Thai and assessed its validity and reliability. Design: Prospectively recruited during January 2012-May 2017. Setting: Multicenter; six Thai tertiary university hospitals. Study Participants: Total of 306 patients with physician-diagnosed drug hypersensitivity. Interventions: Internal consistency and test-retest reliability were evaluated among 68 participants using Cronbach's ? and intra-class correlation coefficient (ICC). The validity of Thai DrHy-Q was assessed among 306 participants who completed World Health Organization Quality of Life-BREF (WHOQOL-BREF-THAI). Construct and divergent validities were assessed for Thai DrHy-Q. Known-groups validity assessing discriminating ability was conducted in Thai DrHy-Q and WHOQOL-BREF-THAI. Main outcome measures: Validity; reliability; single vs. multiple drug allergy; non-severe cutaneous adverse reactions (SCAR) vs. SCAR. Results: Thai DrHy-Q showed good reliability (Cronbach's ? = 0.94 and ICC = 0.8). Unidimensional factor structure was established by confirmatory factor analysis (CFI&TLI = 0.999, RMSEA = 0.02). Divergent validity was confirmed by weak correlation between Thai DrHy-Q and WHOQOL-BREF-THAI domains (Pearson's r = -0.41 to -0.19). Known-groups validity of Thai DrHy-Q was confirmed with significant difference between patients with and without life-threatening SCAR (P = 0.02) and patients with multiple implicated drug classes vs. those with one class (P < 0.01); while WHOQOL-BREF-THAI could differentiate presence of life-threatening SCAR (P < 0.01) but not multiple-drug allergy. Conclusions: Thai DrHy-Q was reliable and valid in evaluating quality of life among patients with drug hypersensitivity. Thai DrHy-Q was able to discriminate serious drug allergy phenotypes from non-serious manifestations in clinical practice and capture more specific drug-hypersensitivity aspects than WHOQOL-BREF-THAI.
AB - Objective: To adapted the Drug Hypersensitivity Quality of Life (DrHy-Q) Questionnaire from Italian into Thai and assessed its validity and reliability. Design: Prospectively recruited during January 2012-May 2017. Setting: Multicenter; six Thai tertiary university hospitals. Study Participants: Total of 306 patients with physician-diagnosed drug hypersensitivity. Interventions: Internal consistency and test-retest reliability were evaluated among 68 participants using Cronbach's ? and intra-class correlation coefficient (ICC). The validity of Thai DrHy-Q was assessed among 306 participants who completed World Health Organization Quality of Life-BREF (WHOQOL-BREF-THAI). Construct and divergent validities were assessed for Thai DrHy-Q. Known-groups validity assessing discriminating ability was conducted in Thai DrHy-Q and WHOQOL-BREF-THAI. Main outcome measures: Validity; reliability; single vs. multiple drug allergy; non-severe cutaneous adverse reactions (SCAR) vs. SCAR. Results: Thai DrHy-Q showed good reliability (Cronbach's ? = 0.94 and ICC = 0.8). Unidimensional factor structure was established by confirmatory factor analysis (CFI&TLI = 0.999, RMSEA = 0.02). Divergent validity was confirmed by weak correlation between Thai DrHy-Q and WHOQOL-BREF-THAI domains (Pearson's r = -0.41 to -0.19). Known-groups validity of Thai DrHy-Q was confirmed with significant difference between patients with and without life-threatening SCAR (P = 0.02) and patients with multiple implicated drug classes vs. those with one class (P < 0.01); while WHOQOL-BREF-THAI could differentiate presence of life-threatening SCAR (P < 0.01) but not multiple-drug allergy. Conclusions: Thai DrHy-Q was reliable and valid in evaluating quality of life among patients with drug hypersensitivity. Thai DrHy-Q was able to discriminate serious drug allergy phenotypes from non-serious manifestations in clinical practice and capture more specific drug-hypersensitivity aspects than WHOQOL-BREF-THAI.
KW - adverse drug reaction
KW - drug hypersensitivity
KW - quality of life
KW - validity and reliability
UR - http://www.scopus.com/inward/record.url?scp=85074626002&partnerID=8YFLogxK
U2 - 10.1093/intqhc/mzy207
DO - 10.1093/intqhc/mzy207
M3 - Article
C2 - 30346532
VL - 31
SP - 527
EP - 534
JO - International Journal for Quality in Health Care
JF - International Journal for Quality in Health Care
SN - 1353-4505
IS - 7
ER -